Matthew Shawn Morris Sells 63,212 Shares of Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 63,212 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $25.33, for a total transaction of $1,601,159.96. Following the sale, the director directly owned 76,651 shares of the company’s stock, valued at approximately $1,941,569.83. The trade was a 45.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, June 26th, Matthew Shawn Morris sold 88,110 shares of Privia Health Group stock. The stock was sold at an average price of $25.33, for a total value of $2,231,826.30.
• On Friday, May 1st, Matthew Shawn Morris sold 17,096 shares of Privia Health Group stock. The stock was sold at an average price of $24.99, for a total value of $427,229.04.
• On Monday, May 4th, Matthew Shawn Morris sold 1,017 shares of Privia Health Group stock. The shares were sold at an average price of $24.96, for a total value of $25,384.32.

Privia Health Group Stock Performance

Privia Health Group stock traded up $0.18 on Tuesday, reaching $25.73. The company’s stock had a trading volume of 863,376 shares, compared to its average volume of 928,529. The company has a market cap of $3.24 billion, a price-to-earnings ratio of 160.82, a PEG ratio of 2.02 and a beta of 0.90. The business’s fifty day moving average price is $23.22 and its 200 day moving average price is $22.95. Privia Health Group, Inc. has a twelve month low of $18.77 and a twelve month high of $26.51.

Privia Health Group (NASDAQ:PRVA) last announced its earnings results on Thursday, May 7th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.08 by $0.11. Privia Health Group had a return on equity of 2.81% and a net margin of 0.97%.The company had revenue of $603.85 million for the quarter, compared to analysts’ expectations of $560.99 million. During the same quarter in the prior year, the business earned $0.22 earnings per share. The business’s revenue for the quarter was up 25.8% on a year-over-year basis. As a group, equities analysts forecast that Privia Health Group, Inc. will post 0.27 earnings per share for the current year.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors have recently modified their holdings of the business. Durable Capital Partners LP raised its stake in shares of Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock worth $291,123,000 after buying an additional 203,842 shares during the last quarter. State Street Corp raised its position in shares of Privia Health Group by 1.5% during the 2nd quarter. State Street Corp now owns 4,171,069 shares of the company’s stock valued at $95,935,000 after acquiring an additional 61,853 shares during the last quarter. Van Berkom & Associates Inc. lifted its stake in shares of Privia Health Group by 5.4% in the 1st quarter. Van Berkom & Associates Inc. now owns 4,053,043 shares of the company’s stock valued at $83,371,000 after purchasing an additional 208,787 shares during the period. Geode Capital Management LLC lifted its stake in shares of Privia Health Group by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock valued at $66,738,000 after purchasing an additional 31,204 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Privia Health Group by 1.6% in the 4th quarter. Principal Financial Group Inc. now owns 2,787,802 shares of the company’s stock worth $66,099,000 after purchasing an additional 43,589 shares during the last quarter. Institutional investors and hedge funds own 94.48% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group lowered their price objective on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Citigroup decreased their price target on shares of Privia Health Group from $34.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, March 3rd. Truist Financial raised their price target on shares of Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Evercore set a $26.00 price objective on shares of Privia Health Group in a research report on Wednesday, April 8th. Finally, Barclays decreased their price objective on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Privia Health Group currently has an average rating of “Moderate Buy” and an average target price of $31.15.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.